Tramadol News and Research

RSS
Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Health Canada approves Labopharm's OLEPTRO for treatment of Major Depressive Disorder

Labopharm monetizes future royalty payment stream for RYZOLT through subsidiary

Labopharm monetizes future royalty payment stream for RYZOLT through subsidiary

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm receives notice about Activis' ANDA for OLEPTRO

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm third quarter total revenue increases to $9.6 million

Labopharm third quarter total revenue increases to $9.6 million

Single injection of morphine to fight persistent pain reduces testosterone level: Research

Single injection of morphine to fight persistent pain reduces testosterone level: Research

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher reports net revenue of $1.1 million for 2010 third quarter

Cipher reports net revenue of $1.1 million for 2010 third quarter

Labopharm, Paladin Labs expand commercial relationship

Labopharm, Paladin Labs expand commercial relationship

Labopharm announces European approval of twice-daily tramadol-acetaminophen

Labopharm announces European approval of twice-daily tramadol-acetaminophen

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail second-quarter total revenues increase 23% to $238.8 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Etoricoxib better than opioid drug tramadol for postoperative pain: Study

Etoricoxib better than opioid drug tramadol for postoperative pain: Study

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Expert to speak on challenges, issues in development, implementation of REMS

Expert to speak on challenges, issues in development, implementation of REMS